Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.

Trial Details

NCT ID
NCT05820841
Phase
PHASE3
Sponsor
Universität des Saarlandes
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • R-miniCHOP + Acalabrutinib
  • R-miniCHOP
Locations (sample)
  • Homburg, Saarland, Germany|49.32637,7.33867
  • Aschaffenburg, Germany|49.97704,9.15214
  • Berlin, Germany|52.52437,13.41053
  • Berlin, Germany|52.52437,13.41053
  • Dresden, Germany|51.05089,13.73832

Key Eligibility Criteria

  • Informed consent
  • Ability to understand the purpose and risks of the study and capable of giving signed informed consent which includes:
  • Compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Authorization to use protected health information/data \[in accordance with the General Data Protection Regulation (GDPR)\].

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →